Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes

Journal of Nuclear Medicine

Volumn 50, Issue 10, 2009, Pages 1683-1691

  Malviya, Gaurav ^a   D'Alessandria, Calogero ^b   Bonanno, Elena ^c   Vexler, Vladimir ^d   Massari, Roberto ^e   Trotta, Carlo ^e   Scopinaro, Francesco ^b   Dierckx, Rudi ^a   Signore, Alberto ^a,b,f  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d PDL BioPharma Inc   (United States)

^e CNR   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biodistribution; Molecular animal imaging; Radiolabeling; Visilizumab

Indexed keywords

CD3 ANTIGEN; CYSTEINE; TRACER; UNCLASSIFIED DRUG; VISILIZUMAB; VISILIZUMAB SUCCINIMIDYL 6 HYDRAZINONICOTINATE TC 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INFLAMMATION; ISOTOPE LABELING; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUALITY CONTROL; SCID MOUSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BINDING, COMPETITIVE; CELL LINE; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOCYTES, MONONUCLEAR; MICE; MOLECULAR PROBE TECHNIQUES; NIACINAMIDE; ORGANOTECHNETIUM COMPOUNDS; QUALITY CONTROL; RADIOIMMUNODETECTION; SUBSTRATE SPECIFICITY; SUCCINIMIDES; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 70349646891     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.059485     Document Type: Article

References (34)

1. Trajkovic V. Nuvion: Protein design labs. Curr Opin Investig Drugs. 2002;3:411-414.
2. Carpenter PA, Appelbaum FR, Corey L, et al. A humanised non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graftversus- host disease. Blood. 2002;99:2712-2719. (Pubitemid 34525356)
3. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 2007;56:2103-2109. (Pubitemid 47195835)
4. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation. 1999;68:1632-1637. (Pubitemid 30004793)
5. Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002;29:1907-1913. (Pubitemid 34988699)
6. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994;57:1537-1543.
7. Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008;127:322-329.
8. Hommes D, Targan S, Dignass A, et al. A phase I study: visilizumab therapy in Crohn's disease refractory to infliximab treatment [abstract]. Gastroenterology. 2006;130:A-111.
9. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:465-471. (Pubitemid 40753799)
10. Norman DJ, Vincenti F, de Mattos AM, et al. Phase I trial of HuM291, a humanised anti-CD3 antibody, in patients receiving renal allograft from living donors. Transplantation. 2000;70:1707-1712. (Pubitemid 32064824)
11. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007;133:1414-1422. (Pubitemid 350029746)
12. Mather SJ, Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med. 1990;31:692-697. (Pubitemid 20179715)
13. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89. (Pubitemid 14091996)
14. Soluri A, Scopinaro F, De Vincentis G, et al. 99MTC [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsy. Anticancer Res. 2003;23:2139-2142. (Pubitemid 36897174)
15. 123I]ioflupane by rat brain. Q J Nucl Med Mol Imaging. 2007;51:204-210.
16. Ishizaka Y, Itoh F, Tahira T, et al. Presence of aberrant transcripts of ret protooncogene in a human papillary thyroid carcinoma cell line. Jpn J Cancer Res. 1989;80:1149-1152. (Pubitemid 20050979)
17. Kawata A, Yoshida M, Okazaki M, et al. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the anti-tumor efficacy of monoclonal antibody. Cancer Res. 1994;54:2688-2694. (Pubitemid 24173759)
18. Shpitz B, Chambers CA, Singhal AB, et al. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pre-treatment with radiation and anti-asialo GM1. J Immunol Methods. 1994;169:1-15. (Pubitemid 24084581)
19. 99mtechnetium- labeled human polyclonal immunoglobulin G. Rheumatol Int. 2001;20:71-77.
20. Ortapamuk H, Hosal B, Naldoken S. The role of Tc-99m polyclonal human immunoglobulin G scintigraphy in Graves' ophthalmopathy. Ann Nucl Med. 2002;16:461-465. (Pubitemid 36013943)
21. Malviya G, de Vries EFJ, Dierckx RA, Signore A. Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Braz Arch Bio Tech. 2008;50:1-13.
22. 99mTc labeled anti-TNFα monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Q J Nucl Med Mol Imaging. 2007;51:334-342.
23. Chianelli M, D'Alessandria C, Conti F, et al. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging. 2006;50:217-225. (Pubitemid 44649661)
24. Barrera P, Oyen WJG, Boerman OC, van Riel PLCM. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:825-828. (Pubitemid 37026491)
25. Malviya G, D'Alessandria C, Lanzolla T, et al. 99m-technetium labeled anti- TNFα antibodies for the therapy decision making and follow-up of patients with rheumatoid arthritis [abstract]. Q J Nucl Med Mol Imaging. 2008;52(suppl 1):13.
26. Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ. 99mTc-rituximab radiolabeled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med. 2006;33:53-59. (Pubitemid 41785309)
27. Malviya G, Lagàna B, Signore A, Dierckx RA. Radiolabeled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Des. 2008;14:2401-2414.
28. 99mTc. Bioconjug Chem. 1999;10:447-453.
29. m-labeled human nonspecific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Br J Radiol. 1997;70:473-481.
30. Becker W, Emmrich F, Horneff G, et al. Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies. Eur J Nucl Med. 1990;17:156-159. (Pubitemid 20355657)
31. Kinne RW, Becker W, Schwab J, et al. Comparison of 99Tcm-labeled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun. 1993;14:667-675. (Pubitemid 23233480)
32. 99mTc]OKT3 scintigraphy to evaluate acute rejection in renal transplants. Transplant Proc. 2004;36:2664-2667.
33. Marcus C, Thakur ML, Huynh TV, et al. Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nucl Med Commun. 1994;15:824-830. (Pubitemid 24317026)
34. Sgro C. Side-effects of a monoclonal antibody, muromomab CD3/Orthoclone OKT3: bibliographic review. Toxicology. 1995;105:23-29. (Pubitemid 126738973)